Apalutamide PROSTAXEN 60mg: Androgen Receptor Blockade Combined with ADT

Overview

Apalutamide is never used alone in prostate cancer; its role is as part of a combination with continuous androgen deprivation therapy. Castration lowers circulating testosterone, but residual androgen-receptor signaling can still drive the disease, so adding a receptor blocker completes the suppression. This combination strategy underpins its use in non-metastatic castration-resistant disease and in metastatic castration-sensitive disease, where deeper axis control is the goal. The 60 mg tablet lets clinicians build the standard daily dose from a fixed, easy-to-count regimen that patients can follow for many months without confusion.

How It Works

Apalutamide binds the ligand-binding domain of the androgen receptor and stops the receptor from moving into the nucleus. Without nuclear translocation, androgen-receptor-dependent transcription cannot proceed, and the growth signals that prostate cancer cells rely on are switched off. Combined with the low testosterone achieved by ADT, the tumor is deprived of both the ligand and the receptor pathway that would otherwise keep it advancing, which is why the two components are given together rather than in sequence.

Indications

• Non-metastatic castration-resistant prostate cancer (nmCRPC)
• Metastatic castration-sensitive prostate cancer (mCSPC) with ADT
• Used with docetaxel in some mCSPC regimens per label

Dosage & Administration

The standard dose is 240 mg once daily, equal to four 60 mg tablets, taken at the same time each day with or without food and swallowed whole. It is always given together with ongoing ADT. For tolerability, the clinician may hold or reduce the dose according to the label, while ADT generally continues unless the care team specifies otherwise, because stopping suppression can permit rapid disease flare in sensitive tumors.

Storage & Sourcing

Store below 30°C in a dry place. Supplied through Beacon and Janssen partner lines as a GMP oral solid with lot-specific certificates of analysis. As an ambient-stable tablet it suits routine B2B distribution to pharmacies and clinics supporting long-term prostate cancer care, and the consistent tablet strength simplifies inventory planning across multi-site oncology networks.

FAQ

Q: Why must apalutamide be combined with ADT?

A: Castration already lowers testosterone, but residual receptor signaling drives disease; apalutamide blocks the receptor so the combination delivers more complete suppression.

Q: What is the standard daily dose?

A: 240 mg once daily, four 60 mg tablets, taken at a consistent time with or without food, together with continued androgen deprivation therapy.

Q: Can the dose be interrupted?

A: Manage toxicity by holding or reducing per label and clinician advice; ADT generally continues unless the team directs otherwise during the interruption.

Q: What should be monitored during treatment?

A: Seizure history, falls and rash are reviewed; skin reactions and thyroid or bone health may be followed during long-term use.